NLRP2 — NLR Family Pyrin Domain Containing 2

NLRP2 — NLR Family Pyrin Domain Containing 2

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f5e9; text-align:center; font-size:1.1em;">NLRP2 — NLR Family Pyrin Domain Containing 2</th></tr>
<tr><th>Gene Symbol</th><td>NLRP2</td></tr>
<tr><th>Full Name</th><td>NLR Family Pyrin Domain Containing 2</td></tr>
<tr><th>Chromosome</th><td>19q13.42</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/55655">55655</a></td></tr>
<tr><th>OMIM</th><td><a href="https://www.omim.org/entry/609364">609364</a></td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000163352</td></tr>
<tr><th>UniProt ID</th><td><a href="https://www.uniprot.org/uniprot/Q9NXD1">Q9NXD1</a></td></tr>
<tr><th>Protein Family</th><td>NOD-like receptor (NLR) family</td></tr>
<tr><th>Associated Diseases</th><td>Alzheimer's Disease, Parkinson's Disease, Epilepsy, Maternal Effect Disorders, Stroke</td></tr>
</table>
</div>

Overview

NLRP2 — NLR Family Pyrin Domain Containing 2

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f5e9; text-align:center; font-size:1.1em;">NLRP2 — NLR Family Pyrin Domain Containing 2</th></tr>
<tr><th>Gene Symbol</th><td>NLRP2</td></tr>
<tr><th>Full Name</th><td>NLR Family Pyrin Domain Containing 2</td></tr>
<tr><th>Chromosome</th><td>19q13.42</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/55655">55655</a></td></tr>
<tr><th>OMIM</th><td><a href="https://www.omim.org/entry/609364">609364</a></td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000163352</td></tr>
<tr><th>UniProt ID</th><td><a href="https://www.uniprot.org/uniprot/Q9NXD1">Q9NXD1</a></td></tr>
<tr><th>Protein Family</th><td>NOD-like receptor (NLR) family</td></tr>
<tr><th>Associated Diseases</th><td>Alzheimer's Disease, Parkinson's Disease, Epilepsy, Maternal Effect Disorders, Stroke</td></tr>
</table>
</div>

Overview

NLRP2 (NLR Family Pyrin Domain Containing 2) is a member of the NOD-like receptor (NLR) family that plays critical roles in innate immunity and inflammasome formation. While NLRP2 has been most extensively studied in the context of reproduction and inflammatory disorders, it is increasingly recognized as an important regulator of neuroinflammation in the brain. Inflammasomes are multimeric protein complexes that activate inflammatory caspases and trigger the maturation of pro-inflammatory cytokines including interleukin-1beta (IL-1beta) and interleukin-18 (IL-18) [@broz2010].

In the brain, NLRP2 is expressed in [neurons](/entities/neurons), [astrocytes](/entities/astrocytes), and [microglia](/cell-types/microglia-neuroinflammation), where it participates in the cellular response to pathological challenges. NLRP2 inflammasome activation has been implicated in the neuroinflammatory components of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), epilepsy, stroke, and traumatic brain injury [@liu2020][@wu2018]. Chronic NLRP2 activation contributes to progressive neuroinflammation and neuronal dysfunction, making it a potential therapeutic target.

This page covers the gene's structure, normal physiological functions, disease associations, expression patterns, and therapeutic implications for neurodegenerative disease research.

Molecular Biology and Structure

Gene Organization and Evolution

The NLRP2 gene spans approximately 27 kb on chromosome 19q13.42 and consists of 10 exons encoding a 975-amino-acid protein with a molecular weight of approximately 114 kDa. NLRP2 belongs to the NLRP subfamily, which includes NLRP1-14 in humans. Among NLRP proteins, NLRP2 shares closest structural and functional similarity with NLRP3, though it has distinct regulatory properties and tissue expression patterns.

Protein Domain Architecture

NLRP2 contains several functional domains typical of NLR proteins:

The NACHT domain contains Walker A (P-loop) and Walker B motifs characteristic of NTP-binding proteins. ATP binding and hydrolysis regulate NLRP2 oligomerization and inflammasome assembly.

Structural Insights

Cryo-EM studies of NLRP3 have provided insights into inflammasome architecture that likely apply to NLRP2:

• Inflammasomes form wheel-like structures with the NACHT domains at the center
• The LRR domains form the outer "spokes"
• ASC adapters bind through PYD interactions to form filamentous structures
• This architecture allows recruitment and activation of pro-caspase-1

Post-Translational Modifications

NLRP2 is regulated by several post-translational modifications:

• Phosphorylation: Kinases including PKR and CK2 can phosphorylate NLRP2
• Ubiquitination: NLRP2 is subject to both K63-linked and linear ubiquitination
• SUMOylation: Affects inflammasome assembly and activity
• ADP-ribosylation: PARP1-mediated modification affects NLRP2 function

Function in Biological Systems

Inflammasome Assembly and Activation

NLRP2 forms inflammasome complexes that activate caspase-1, leading to cytokine maturation and pyroptotic cell death [@schroder2009]:

Activation triggers:

• Mitochondrial dysfunction and ROS production
• Mitochondrial DNA release into cytosol
• Potassium efflux
• Calcium influx
• Cellular stress from various pathogens and damage signals

Inflammasome Regulation

NLRP2 activity is tightly regulated:

• Autoinhibition: LRR domain folds over NACHT to maintain inactive state
• Positive regulation: NEK7 is required for NLRP3/NLRP2 activation
• Negative regulation: ASC limit inflammasome size; ubiquitination targets NLRP2 for degradation
• Cross-talk: NLRP2 can interact with NLRP3 in some contexts

Cytokine Production

Active NLRP2 inflammasomes produce:

• IL-1β: Potent pro-inflammatory cytokine driving neuroinflammation
• IL-18: IFN-γ-inducing cytokine; implicated in autoimmune responses
• Gasdermin D: Pore-forming protein that drives pyroptosis

Non-Inflammasome Functions

NLRP2 has inflammasome-independent roles:

• Transcriptional regulation: Can influence gene expression through ASC-independent mechanisms
• Metabolic regulation: Modulates cellular metabolism in some contexts
• Cell cycle regulation: May affect cell proliferation and survival

Expression Pattern

Brain Expression

NLRP2 exhibits distinct expression patterns in the nervous system:

| Brain Region | Expression Level | Cell Types |
|--------------|-----------------|------------|
| Cerebral Cortex | Moderate-High | Cortical neurons, astrocytes |
| Hippocampus | High | Pyramidal neurons, granule cells |
| Cerebellum | Moderate | Purkinje cells, granule cells |
| Hypothalamus | Moderate | Various neuron populations |
| Spinal Cord | Moderate | Motor neurons, interneurons |

Cellular Distribution

In the brain, NLRP2 is expressed in:

• Neurons: Primarily in the soma and proximal dendrites
• Astrocytes: Moderate expression throughout cytoplasm
• Microglia: Lower expression than NLRP3, but functional
• Oligodendrocytes: Limited expression

Subcellular Localization

NLRP2 localizes to:

• Cytoplasm: Primary location, diffuse distribution
• Mitochondria: Partial mitochondrial association, particularly under stress
• Endoplasmic reticulum: Interaction with ER stress pathways
• Nucleus: Some nuclear localization reported

Developmental and Age-Related Expression

NLRP2 expression shows:

• Moderate expression during development
• Increased expression in aging brain
• Upregulation in various pathological conditions

Disease Associations

Alzheimer's Disease

NLRP2 inflammasome activation contributes to [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis through several mechanisms [@liu2020]:

Neuroinflammation:

• NLRP2 is activated by amyloid-beta oligomers in neurons and microglia
• IL-1β release drives chronic neuroinflammation
• Inflammatory cascade contributes to synaptic dysfunction

• NLRP2 can cooperate with NLRP3 in some contexts
• Cross-talk amplifies inflammasome activation

• Inflammasome activation may influence tau phosphorylation
• Chronic inflammation contributes to tau spread

• NLRP2 inhibitors may reduce neuroinflammation
• Combined NLRP2/NLRP3 targeting may be beneficial

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease), NLRP2 contributes to dopaminergic neuron degeneration [@wu2018]:

Alpha-synuclein-induced activation:

• NLRP2 is activated by α-synuclein aggregates
• Inflammasome activation in dopaminergic neurons
• Contributes to chronic neuroinflammation in substantia nigra

• NLRP2 in microglia contributes to neuroinflammation
• Pro-inflammatory cytokine release damages neurons

• NLRP2 inhibition may protect dopaminergic neurons
• Anti-inflammatory strategies targeting NLRP2

Epilepsy

NLRP2 is strongly implicated in [epilepsy](/diseases/epilepsy) pathogenesis [@wang2021]:

Seizure-induced inflammation:

• NLRP2 inflammasome activates in response to seizure activity
• IL-1β production contributes to hyperexcitability
• Contributes to seizure recurrence and progression

• NLRP2 mutations associated with epileptic encephalopathy
• Some mutations cause gain-of-function inflammasome activation

• NLRP2 inhibitors may reduce seizure frequency
• Anti-inflammatory approaches for drug-resistant epilepsy

Stroke and Traumatic Brain Injury

NLRP2 contributes to secondary brain injury:

Ischemic stroke:

• NLRP2 activates in response to hypoxia and reperfusion
• Inflammasome-driven inflammation exacerbates damage
• Contributes to blood-brain barrier disruption

• Mechanical injury activates NLRP2
• Contributes to post-traumatic neuroinflammation
• May impair recovery

Reproductive Disorders

NLRP2 is most well-known for roles in:

• Maternal effect disorders: NLRP2 mutations cause preeclampsia and recurrent pregnancy loss
• Fertility: Required for successful embryonic implantation
• Placental function: Important for trophoblast development

Mechanism of Pathogenesis

Primary Pathogenic Mechanisms

Dysregulated NLRP2 signaling contributes to neurodegeneration through:

Downstream Consequences

• Microglial activation and proliferation
• Astrocyte reactivity
• Impaired neurogenesis
• Oxidative stress
• Excitotoxicity

Therapeutic Implications

Therapeutic Strategies

Small molecule inhibitors:

• Direct NLRP2 inhibitors under development
• Targeting upstream activators
• Caspase-1 inhibitors (reduces downstream effects)

• Anti-IL-1β antibodies (canakinumab)
• IL-1 receptor antagonists (anakinra)
• ASC inhibitors

• Existing anti-inflammatory drugs
• Metabolic modulators
• Antioxidants

Clinical Considerations

• NLRP2 vs. NLRP3 selectivity matters
• Timing of intervention important
• Blood-brain barrier penetration required

See Also

• [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome)
• [Neuroinflammation Pathways](/mechanisms/neuroinflammation)
• [Alzheimer's Disease Mechanisms](/diseases/alzheimers-disease/mechanisms)
• [Parkinson's Disease Mechanisms](/diseases/parkinsons-disease/mechanisms)
• [Epilepsy Mechanisms](/mechanisms/epilepsy-pathogenesis)
• [Pyroptosis in Neurodegeneration](/mechanisms/pyroptosis-neurodegeneration)
• [Microglia in Neuroinflammation](/cell-types/microglia-neuroinflammation)
• [Cytokine Signaling in Brain](/mechanisms/cytokine-signaling-neurodegeneration)
• [Innate Immunity in Neurodegeneration](/mechanisms/innate-immunity-neurodegeneration)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving NLRP2 — NLR Family Pyrin Domain Containing 2 discovered through SciDEX knowledge graph analysis: